Automated Auditory Brainstem Response: A Proposal for an Initial Test for Healthy Newborn Hearing Screening with a Focus on the Test Time

healthy newborns due to its lower false-positive and referral rates, high specificity, and also its’ ability to diagnose auditory neuropathy spectrum disorder combination with Transient Evoked Otoacoustic Emissions test. On the other hand, the test time can be a disadvantage. With technological advancements, a new generation Automated Auditory Brainstem Response has been developed which is faster. The new design of the Automated Auditory Brainstem Response is designed with a coupler that does not contain disposable electrodes is available at an acceptable cost. The aim of this study was comparing the new generation’s Automated Auditory Brainstem Response and Transient Evoked Otoacoustic Emissions test by regarding to their test times. The results were then compared with those in previously published literature. Methods: Two hundred and sixty healthy infants were included in the study. The hearing screening of all infants was performed using Transient Evoked Otoacoustic Emissions and Automated Auditory Brainstem Response test devices with new, improved technology. The Ero-ScanTM (Maico, Berlin, Germany) test system was used for the Transient Evoked Otoacoustic Emissions, and the newly designed Maico MB11 BERAphone (Maico-Berlin, Germany) Auditory Brainstem Response screening device with three electrodes in one cap was used for the Automated Auditory Brainstem Response test. Results: Mean age of babies was 60.7±51.3 hours, and age range was 4hours-312hours. The test times for the Transient Evoked Otoacoustic Emissions were 13.68±9.2s and 14.04±9.4s, and for the Automated Auditory Brainstem Response, they were 39.15±22.2s and 45,25±23,9s for the right and left ears respectively. Conclusions: Although the Automated Auditory Brainstem Response test time is statistically longer than the Transient Evoked Otoacoustic Emissions, the amount of time it takes has been significantly shortened by the new technology. This finding enhances the value of the new generation Automated Auditory Brainstem Response technology usage as an initial test for newborn hearing screening.